Authors
Jeffery M Klco, Christopher A Miller, Malachi Griffith, Allegra Petti, David H Spencer, Shamika Ketkar-Kulkarni, Lukas D Wartman, Matthew Christopher, Tamara L Lamprecht, Nicole M Helton, Eric J Duncavage, Jacqueline E Payton, Jack Baty, Sharon E Heath, Obi L Griffith, Dong Shen, Jasreet Hundal, Gue Su Chang, Robert Fulton, Michelle O'Laughlin, Catrina Fronick, Vincent Magrini, Ryan T Demeter, David E Larson, Shashikant Kulkarni, Bradley A Ozenberger, John S Welch, Matthew J Walter, Timothy A Graubert, Peter Westervelt, Jerald P Radich, Daniel C Link, Elaine R Mardis, John F DiPersio, Richard K Wilson, Timothy J Ley
Publication date
2015/8/25
Journal
JAMA
Volume
314
Issue
8
Pages
811-822
Publisher
American Medical Association
Description
Importance
Tests that predict outcomes for patients with acute myeloid leukemia (AML) are imprecise, especially for those with intermediate risk AML.
Objectives
To determine whether genomic approaches can provide novel prognostic information for adult patients with de novo AML.
Design, Setting, and Participants
Whole-genome or exome sequencing was performed on samples obtained at disease presentation from 71 patients with AML (mean age, 50.8 years) treated with standard induction chemotherapy at a single site starting in March 2002, with follow-up through January 2015. In addition, deep digital sequencing was performed on paired diagnosis and remission samples from 50 patients (including 32 with intermediate-risk AML), approximately 30 days after successful induction therapy. Twenty-five of the 50 were from the cohort of 71 patients, and 25 were new, additional cases.
Exposures
Whole-genome or …
Scholar articles
JM Klco, CA Miller, M Griffith, A Petti, DH Spencer… - Jama, 2015